Propafenone‐ <i>vs</i> . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure — Yi Lin (2025) | RDL Network
Propafenone‐ <i>vs</i> . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure
Article 2025 en
Authors
YL
Yi Lin
BC
Bi‐Li Chen
CH
Chien‐Yi Hsu
Abstract
1 min read
Propafenone was not significantly associated with increased risk of proarrhythmia and mortality when compared to amiodarone in atrial fibrillation patients with heart failure in contemporary real-world settings. Prospective studies are needed to determine whether propafenone should definitely be avoided in these patients.
Monika Kozieł, M Mihajlović, Milan Nedeljković, Nikola Pavlović, Vilma Paparisto, Ljilja Musić, Elina Trendafilova, Anca Rodica Dan, Zumreta Kušljugić, Gheorghe‐Andrei Dan, Professor Gregory Lip, Tatjana Potpara
Tommaso Bucci, Katarzyna Nabrdalik, Alena Shantsila, Giulio Francesco Romiti, Wee‐Siong Teo, Hyung Wook Park, Wataru Shimizu, Hung‐Fat Tse, Marco Proietti, Tze‐Fan Chao, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.